Trial reportThe Lancet. Global health2025
Scaling an intervention for the engagement of people with HIV who inject drugs into care in Viet Nam: an implementation-effectiveness, cluster-randomised trial.
Trial report in The Lancet. Global health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03952520 (Scaling up HIV Prevention Trials Network), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Scaling up HIV Prevention Trials Network (HPTN) 074: a Cluster Randomized Implementation Trial of an Evidence-based Intervention for Antiretroviral Therapy for PWID in Vietnam
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
backgroundGovernmental agencies often implement evidence-based interventions with a one-size-fits-all approach, which ignores site differences. We compared a tailored approach, accounting for sites' needs, to a standard approach to implement systems navigation and psychosocial counselling (SNaP) to improve HIV outcomes for people who inject drugs (PWID).
methodsWe conducted a hybrid type 3 implementation-effectiveness, cluster-randomised trial at HIV testing sites in ten provinces in Viet Nam. SNaP comprised two systems navigation sessions, in person or by telephone, and at least one psychosocial counselling session. Sites were randomised (1:1) to a standard approach (a package of 15 implementation strategies) or a tailored approach (standard strategies plus a menu of ten additional strategies). Study participants included navigators and counsellors of SNaP, site directors, other staff, and PWID with HIV. Sites were chosen based on the number of HIV tests performed, HIV positivity rate, and the size of the PWID population covered by the site. PWID with HIV were aged 18 years or older, not on antiretroviral therapy (ART) at enrolment, and had used injection drugs in the previous 6 months. The primary outcomes were fidelity (implementation outcome) and ART initiation (effectiveness outcome); secondary effectiveness outcomes were the current use of ART and medications for opioid use disorder and viral suppression. Analyses were conducted with generalised linear models or generalised estimating equations. The study was registered with ClinicalTrials.gov (NCT03952520) and is complete.
findingsOn Feb 27, 2020, 42 testing sites were randomised to two approaches (tailored: n=21; standard: n=21), and participants were recruited to the trial between May 8, 2020, and Aug 17, 2022, resulting in the inclusion of 277 staff (tailored: n=141; standard: n=136) and 723 PWID with HIV (tailored: n=364; standard: n=359). Clinic fidelity scores (range 0-200) were higher with the tailored approach (mean 151·4 [SD 21·4]) than the standard approach (114·1 [13·5]; adjusted mean difference 37·3 points [95% CI 26·5-48·1]). Nearly all follow-up participants receiving SNaP initiated ART (tailored: 345 [99%] of 347; standard: 334 [99%] of 338; adjusted risk difference 1·3 percentage points [95% CI 0·7-1·9]; intraclass correlation coefficient -0·01). Viral suppression among PWID was substantially higher in the tailored approach arm (adjusted prevalence difference 15·8% [95% CI 5·0-26·5]); no other secondary effectiveness outcomes were significant. There were 63 (9%) deaths among 685 follow-up participants, with 14 (2%) dying before baseline assessment.
interpretationA tailored approach with rapid needs assessment before and during implementation to address local testing site barriers in Viet Nam improved fidelity of SNaP delivery. The tailored approach had a small effect on ART initiation; viral suppression improved substantially.
fundingUS National Institutes of Health, US National Institute of Drug Abuse, and US National Institute for Allergy and Infectious Diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.